BFLY · Butterfly Network, Inc. · Stock research

Current Thesis

The leg an investor is buying here is the re-rating of Butterfly from a handheld-ultrasound device vendor into an Ultrasound-on-Chip licensor. Butterfly Embedded (formerly Octiv) went from a line on the earnings deck to dated commercial proof inside eight days in late June: on 2026-06-18 Midjourney Medical unveiled a full-body tomographic scanner built on 40 Butterfly Ultrasound-on-Chip modules per system (~60-second whole-body scan) under a co-development/licensing deal worth up to $74M over five years (economics first filed in a Form 8-K 2025-11-17: $15M one-time + $10M annual license + up to $9M milestones), and on 2026-06-25 a second Embedded partner, Aleph Neuro, published 3D brain imaging on the same platform. That reframed the multiple story from a device comp to a software/royalty comp. The fundamental narrative is intact and still building, but the tape has moved ahead of it: shares doubled from the low-$4s in early June to a 52-week high of $8.94, whipsawed 18% intraday, and have spent the three weeks since digesting that move with no follow-on Embedded license and a news flow that has thinned to generic index-mover mentions (2026-07-06, 2026-07-07). The next real event is a binary Q2 print roughly three weeks out. The theme has cooled from ACCELERATING to MATURING — narrative valid, but the easy momentum leg is spent and the setup now waits on the print rather than leading it.

Bullish and bearish views on Butterfly Network, Inc.

The model's bull view on Butterfly Network, Inc. (BFLY), in brief: Midjourney Medical deal (announced 2026-06-18; economics filed 8-K 2025-11-17): up to $74M over five years, current prototype at 40 Ultrasound-on-Chip modules per system with future generations expected to use "substantially more." Asset-light licensing revenue is what supports… The bear view: Insiders sold the first half of this move. Both cases follow in full.

Bull Case

• Midjourney Medical deal (announced 2026-06-18; economics filed 8-K 2025-11-17): up to $74M over five years, current prototype at 40 Ultrasound-on-Chip modules per system with future generations expected to use "substantially more." Asset-light licensing revenue is what supports a software multiple over a hardware multiple.
• Second Embedded validation within a week — Aleph Neuro 3D brain imaging (2026-06-25) — shows the chip generalizes past handheld ultrasound into tomographic and neuro imaging, signaling a licensing pipeline rather than a single marquee customer.
• Q1 2026 (reported 2026-04-30): revenue $26.5M, +25% YoY, ~69% gross margin, Butterfly Embedded revenue +147% YoY. FY2026 guide reaffirmed at $117–121M (~20–24% growth); Q2 guided to $27–31M.
• First FDA-cleared "blind sweep" AI guidance tool (Q1 2026) lets minimally-trained users capture diagnostic images, extending the addressable market into primary care, global health and home settings.
• Balance sheet: ~$138M cash with low debt (latest filings) funds the Embedded build-out without near-term dilution pressure.
• Loss narrowing: adjusted EBITDA loss $6.1M in Q1 versus $9.1M a year earlier — a trajectory that underwrites a re-rate if ~25% top-line growth holds through the Q2 print.

Bear Case

• Insiders sold the first half of this move. Founder Jonathan Rothberg filed intent to sell 352k shares (2026-01-06); insiders were net sellers of ~$6.2M over the trailing year. Distribution into strength with no offsetting insider buying is the primary tell against the bull case.
• The double ran on Midjourney headline flow plus retail social velocity on a ~$2B small-cap, punctuated by an 18.8% single-session reversal to $7.22 in late June. Reflexive spikes of that kind round-trip fast once the headline cadence pauses — and it has paused, with no dated Embedded follow-on since 2026-06-25.
• The $74M contract spans five years (~$10M/yr base) — material against a $117–121M revenue base but not transformational per year, and contingent on Midjourney's unproven whole-body screening business clearing FDA and securing reimbursement. Benzinga (2026-06-18) flagged both hurdles explicitly.
• Valuation carries no cushion into a miss: roughly 10–11x FY26 sales for a still-unprofitable name means a Q2 print at the low end of the $27–31M guide, or soft FY commentary, resets the multiple quickly.

Setup & Price Structure

The chart is a spent parabola working off its extension, not a fresh breakout. The June run took price from the low-$4s base to a 52-week high of $8.94 in about three weeks — a clean double — then printed an 18.8% reversal to $7.22, defining the immediate risk band. The Midjourney breakout base sits near $7.00; a hold above it keeps the re-rate structurally alive, while a loss of it opens the unfilled gap toward the $5.70 shelf, and beneath that the pre-Midjourney low-$4s launchpad. With the news flow thinned to generic "stocks moving higher" baskets (2026-07-06, 2026-07-07) and no follow-on license dated, momentum has decayed into a range rather than extended. For a name in this playbook, strength is the setup — but the strength has already been paid out and the next directional input is the print, not the tape. Fresh exposure ahead of that print is a probe at most; the higher-quality entry is a post-earnings continuation on a beat-and-hold above the base, or a reclaim off a lower gap-fill, not a chase of a stalled leg into binary risk.

Catalyst Calendar (next 30 days)

• ~2026-08-06 (est.): Q2 2026 earnings — the binary. Q1 was reported 2026-04-30; Q2 typically lands late July/early August. Bar to clear: revenue in the guided $27–31M range, FY $117–121M reaffirmed or raised, and Butterfly Embedded revenue growth holding near the +147% Q1 pace. Avoid fresh full-size exposure into an unconfirmed print.
• Unscheduled, highest-leverage: a signed follow-on Butterfly Embedded chip-licensing deal (a third partner after Midjourney and Aleph Neuro). None is dated; a signing would re-accelerate the theme and is the cleanest bull trigger.
• Unscheduled, bearish watch: follow-on insider Form 4s near the highs — continued distribution after the Cashman/Rothberg sales would confirm the tape-vs-narrative divergence.
• Secondary: a HomeCare commercial agreement, targeted for H1 2026 and now running late; any dated announcement widens the device story beyond the Embedded license.

What Would Change Our Mind

The bull structure stays intact while price holds the late-June base and the Embedded licensing cadence continues. Secondary breaks: a Q2 print below the $27M low end of guide or a cut to the $117–121M FY range; continued insider distribution into any strength with no offsetting Form 4 buying; or the theme flipping to SATURATED — social velocity rolling over with no third Embedded partner to refresh the story. On the upside, a signed third Embedded license, or a Q2 beat above $31M with raised FY guidance, restores the theme to ACCELERATING and reopens the parabolic case toward and through the $8.94 high.

Correlation Notes

BFLY trades as a high-beta small-cap medtech riding two overlapping baskets. It moves with risk-on retail/small-cap momentum flow — it was grouped with QuantumScape and Bloom Energy in the 2026-06-19 "on investors' radar" basket and printed +31.3% alongside other high-momentum movers on 2026-06-18 — so it is sensitive to broad risk appetite and social-flow rotation. Its Embedded licensing angle also gives it secondary correlation to AI-silicon/semiconductor sentiment (it moved the same 2026-06-18 session as Micron and Marvell). Idiosyncratic catalyst days (Midjourney/Embedded headlines, the Q2 print) decouple it from SPY entirely, with single-session swings of 18–31%. Position sizing should assume two-sided gap risk and treat the name as a narrative-driven small-cap, not a market-tracking medtech.